晚期胃肠间质瘤姑息手术的安全性与临床获益分析

doi:10.3969/j.issn.1009-976X.2015.06.001

摘要/Abstract

摘要：

【摘要】目的研究晚期胃肠间质瘤患者经过了酪氨酸激酶抑制剂治疗后接受姑息手术的安全性和对预后的影响。方法〓回顾性研究选取中山大学肿瘤防治中心2002年1月~2008年12月间治疗晚期胃肠间质瘤患者,分成两组,手术组和未手术组。两组分别比较临床病理因素和预后的差异。结果〓总共有156例患者入组本研究,其中87例患者接受了姑息手术的,69例患者未接受手术治疗,两组临床病理因素并无明显差异。接受手术的患者中,共有4例(4.6%)患者出现了手术相关并发症,无手术相关死亡。中位随访时间23.7个月,手术组患者其总体生存时间(Overall Survival, OS)和无进展生存时间(Progression-free Survival, PFS)均明显长于未手术组患者,中位PFS分别为46.1个月(手术组)和33.8个月(未手术组),两组2年无疾病生存率分别为:89.7% vs 85.5%, P<0.01,结果具有显著的统计学差异。类似的,中位OS在两组分别为54.8个月(手术组)和40.4个月(未手术组),P<0.01,结果具有统计学意义。亚组分析发现,不论是原发于胃或非胃,原发突变位于c-KIT外显子11,手术组预后均好于非手术组。结论〓晚期胃肠间质瘤患者酪氨酸激酶抑制剂后反应有效的患者,手术安全性良好,接受手术可改善患者预后。

关键词: 手术, 预后, 安全性, 胃肠间质瘤

Abstract:

【Abstract】〓Objective〓To study the safety and clinical benefits of the advanced gastrointestinal stromal tumor (GIST) patients who underwent palliative surgery after tyrosine kinase inhibitors (TKIs) treatment. Methods〓We evaluated the safety and outcomes in a single institution series of advanced GIST patients from January 2002 to December 2008. Patients were categorized into two groups based on whether underwent surgical resection. Results〓156 patients had been recruited in this study, including 87 patients underwent surgical resection and 69 patients kept on TKIs treatment. There was no difference in the clinicopathological features between two groups, and 4 patients had surgical complications. Median follow-up was 23.7 months. The OS and PFS of the patients in surgical group were longer than the non-surgical group, PFS: 46.1 months vs 33.8 months (P<0.01), OS: 54.8 months vs 40.4 months and the 2 years progression-free disease rate was 89.7% vs 85.5%,P<0.01,respectively. Conclusion〓Patients with advanced GISTs have prolonged overall survival after debulking procedures. Surgery for patients with metastatic GIST who have responsive disease after TKIs treatment should be considered.

Key words: Gastrointestinal stromal tumor, Safety, Prognosis, Surgery

中图分类号:

R656
R735

邱海波国婧刘学超沙维斯聂润聪吴婷孙晓卫周志伟. 晚期胃肠间质瘤姑息手术的安全性与临床获益分析[J]. 岭南现代临床外科, 2015, 15(06): 647-652.

Qiu Haibo,Guo Jing,Liu Xuechao,Seeruttum Sharvesh Raj,Nie Runcong,Wu Ting,Sun Xiaowei,Zhou Zhiwei. Safety and clinical benefits of palliative surgery for metastatic gastrointestinal stromal tumor[J]. Lingnan Modern Clinics in Surgery, 2015, 15(06): 647-652.

参考文献

参考文献
1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.
3. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-5.
4. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
6. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-78.
7. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
8. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
9. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
10. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.
11. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7.
12. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-9.
13. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
14. Zhang J, Fujimoto J, Wedge DC, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256-9.
15. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-31.
16. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-52.
17. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
18. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.

[1]	欧欣瑜, 陆艺文, 刘志瀚, 苏士成. 术中导航系统在腔镜乳腺癌保乳根治术中的应用：病例报告[J]. 岭南现代临床外科, 2022, 22(1): 1-5.
[2]	何冲, 周姝睿, 李雅晴, 陈少杰, 练国达, 陈尚祥, 黄开红. 胰腺癌预后相关铁死亡基因筛选及预后预测模型构建[J]. 岭南现代临床外科, 2022, 22(1): 14-23.
[3]	陈海明, 许玲玲, 李建光, 罗惠明. 快速康复外科策略在环状混合痔围手术期治疗中的应用[J]. 岭南现代临床外科, 2022, 22(1): 75-78.
[4]	刘伟. 恶性脑胶质瘤单放和放化疗临床疗效5年随诊分析[J]. 岭南现代临床外科, 2022, 22(1): 89-93.
[5]	何旭辉, 郑潮顺, 郭跃跃, 张隆盛, 邢泽华, 林本丹. 21例颈椎前路手术的加速康复外科理念应用体会[J]. 岭南现代临床外科, 2022, 22(1): 98-102.
[6]	朱晨, 张萌, 王泽, 贾建东. 巨大乳腺交界性叶状肿瘤一例[J]. 岭南现代临床外科, 2022, 22(1): 105-109.
[7]	胡明超, 朱宝松. NDC1基因在结肠癌中诊断及预后价值的生物信息学分析：一项基于TCGA数据库的研究[J]. 岭南现代临床外科, 2021, 21(06): 598-602.
[8]	宋燕州, 康志龙, 苏一男, 张毅明, 赵新, 李志伟, 李伟. NEK7在原发性肝细胞肝癌患者中表达及其临床意义[J]. 岭南现代临床外科, 2021, 21(06): 608-613.
[9]	曹洪涛, 王晓龙, 陈亮, 林波, 汤婷婷, 马克强, 嵇腾飞, 曹天生, 王健, 张文伟, 杨建荣, 卢卓才, 由田, 何青青, 黄敬敏, 周堤侠. SOX新辅助化疗在进展期胃癌的治疗体会[J]. 岭南现代临床外科, 2021, 21(06): 631-635.
[10]	杨剑敏, 邹素文, 李敏滢, 区俏彦. 乳腺纤维腺瘤真空辅助旋切与开放手术对泌乳功能的影响[J]. 岭南现代临床外科, 2021, 21(06): 636-639.
[11]	谢韵韵, 吴贤江, 戴磊, 张伟东, 王迎春. 经口腔前庭腔镜甲状腺癌根治术的临床实践及与开放性手术比较[J]. 岭南现代临床外科, 2021, 21(06): 645-650.
[12]	吴卓鹏, 杨劼. 胸外科手术后继发乳糜胸的防治[J]. 岭南现代临床外科, 2021, 21(06): 688-692.
[13]	沈涛, 卢珠明, 段楚骁, 张东熙, 叶敏, 林志潮. 同时性多原发肺癌淋巴结转移规律的临床研究[J]. 岭南现代临床外科, 2021, 21(05): 561-565.
[14]	王道笃, 赵其炯, 周志标, 何永越. 基于铁死亡相关基因构建肝细胞癌的预后模型[J]. 岭南现代临床外科, 2021, 21(04): 419-424.
[15]	关健华, 温坚坤, 林启谋, 黄文俊. 手术切除联合植入缓释型5-FU在局部区域复发的乳腺癌患者中的应用分析（附27例病例数据分析）[J]. 岭南现代临床外科, 2021, 21(04): 428-431.